Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives

Recruiting now

Conditions studied: Crohn Disease (CD)

In brief

The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease. This study will be conducted within Work Package 3 (WP3) of the INTERCEPT project, a consortium funded by the Innovative Health Initiative (IHI). The research will take place across 28 centres in seven countries: Portugal, Spain, France, Italy, the Netherlands, Sweden, and Poland. To achieve the study objectives, individuals with Crohn's disease (referred to as patients) will be invited to participate and to engage their eligible first-degree relatives. At the baseline visit, the patient's physician will complete a clinical questionnaire covering disease history, treatments, and previous interventions. At the same time, first-degree relatives (parents, siblings, or children) will donate a blood sample for serum isolation and, optionally, a whole blood and stool sample. They will also complete a questionnaire regarding their health status, habits, and preferences. Follow-up questionnaires will be administered every six months to monitor the onset of symptoms or behavioural changes.

Key facts

Study ID

NCT07316621

Run by

GLSMED Learning Health S.A.

People needed

10000

Starts

2026-04-01

Expected to finish

2029-12-31

Last updated by the study team

2026-07-29

Who can join

Age: 16 and older, up to 35. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female participants, between 16 and 35 years old
• FDR (parent, full-siblings or offspring) from a patient with an established diagnosis of CD
• Participants able to understand the information provided to them and to give written informed assent or consent for the study.

You may not qualify if…

• Prior diagnosis of IBD
• Any legal or medical condition that limits the information and participation in the study
• Inability to verify CD diagnosis in the proband
• Participants unwilling or unable to provide informed written consent
• Participants unwilling or unable to donate blood for serum

Where it is running

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma, Italy (enrolling)
• AUMC — Amsterdam, Netherlands (enrolling)
• UMCG — Groningen, Netherlands (enrolling)
• Państwowy Instytut Medyczny MSWiA w Warszawie — Warsaw, Poland (enrolling)
• Hospital Beatriz Ângelo — Lisbon, Portugal (enrolling)
• Hospital da Luz Lisboa — Lisbon, Portugal (enrolling)
• Hospital dos Capuchos — Lisbon, Portugal (enrolling)
• Hospital Santa Maria — Lisbon, Portugal (enrolling)
• Hospital Galdakao-Usansolo — Galdakao, Spain (enrolling)
• Örebro University Hospital — Örebro, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.